Repros Therapeutics (RPRX) Shares Up 7.5%

Repros Therapeutics Inc. (NASDAQ:RPRX)’s share price shot up 7.5% during trading on Tuesday . The company traded as high as $0.48 and last traded at $0.43. 740,800 shares traded hands during mid-day trading, an increase of 20% from the average session volume of 616,321 shares. The stock had previously closed at $0.40.

Separately, S&P Equity Research decreased their price objective on shares of Repros Therapeutics from $0.49 to $0.39 in a report on Monday, November 20th.

Repros Therapeutics (NASDAQ:RPRX) last released its quarterly earnings data on Monday, November 13th. The biotechnology company reported ($0.04) EPS for the quarter, topping analysts’ consensus estimates of ($0.28) by $0.24. The firm had revenue of $0.30 million during the quarter. Repros Therapeutics had a negative net margin of 4,242.73% and a negative return on equity of 894.22%.

A hedge fund recently raised its stake in Repros Therapeutics stock. Allegis Investment Advisors LLC grew its position in shares of Repros Therapeutics Inc. (NASDAQ:RPRX) by 8.9% in the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 398,792 shares of the biotechnology company’s stock after acquiring an additional 32,602 shares during the quarter. Allegis Investment Advisors LLC owned about 1.49% of Repros Therapeutics worth $183,000 as of its most recent filing with the SEC. Hedge funds and other institutional investors own 13.59% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This story was originally posted by Community Financial News and is the sole property of of Community Financial News. If you are accessing this story on another publication, it was illegally stolen and republished in violation of U.S. and international copyright legislation. The correct version of this story can be read at

About Repros Therapeutics

Repros Therapeutics, Inc is a biopharmaceutical company focused on the development of new drugs to treat hormonal and reproductive system disorders. The Company’s product candidates include enclomiphene, which is a single isomer of clomiphene citrate, an orally active small molecule compound, and Proellex, which is an orally administered selective blocker of the progesterone receptor in women, for the treatment of uterine fibroids and endometriosis.

What are top analysts saying about Repros Therapeutics Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Repros Therapeutics Inc. and related companies.


Leave a Reply

share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit